Hepatology · Article 200

How Should Cholangiocarcinoma Surveillance Be Performed in Primary Sclerosing Cholangitis?

Cholangiocarcinoma surveillance PSC requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

Cholangiocarcinoma surveillance PSC clinical reference — Related free clinical resource: Guideline-Based Management in Hepatology.

Cholangiocarcinoma surveillance PSC: practical clinical approach

This page focuses on Cholangiocarcinoma surveillance PSC with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for Cholangiocarcinoma surveillance PSC

Clinical takeaway: For Cholangiocarcinoma surveillance PSC, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: Adults with large-duct PSC should undergo regular surveillance for cholangiocarcinoma and gallbladder malignancy. AASLD guidance recommends annual abdominal imaging, preferably MRI/MRCP, with or without serum CA 19-9. Surveillance is not recommended for pediatric PSC or small-duct PSC in the same manner. New or worsening cholestasis, weight loss, jaundice or a relevant stricture should trigger diagnostic evaluation rather than simply waiting for the next annual scan. ERCP is used for tissue acquisition—cytology plus FISH—and therapeutic drainage when indicated.

MRI/MRCP is preferred for routine surveillance

It evaluates intrahepatic and extrahepatic ducts without the infectious/pancreatitis risk of screening ERCP.

CA 19-9 is supportive, not diagnostic

It can be elevated from cholangitis or obstruction and may be uninformative in Lewis-antigen-negative individuals.

Relevant strictures need tissue

ERCP with brush cytology and FISH is recommended when there is a concerning stricture or clinical change.

Practical clinical algorithm

1. Enroll adults with large-duct PSC in annual MRI/MRCP surveillance.

2. Consider CA 19-9 as an adjunct.

3. Investigate new jaundice, worsening cholestasis or weight loss promptly.

4. For relevant strictures, perform ERCP with cytology and FISH.

5. Drain obstruction when clinically indicated.

6. Refer suspicious or confirmed CCA early to a multidisciplinary hepatobiliary/transplant oncology center.

Common mistakes to avoid

Using ERCP annually as a screening test.
Relying on CA 19-9 alone.
Waiting a year despite new jaundice.
Failing to obtain FISH when sampling a relevant stricture.
Ignoring gallbladder cancer surveillance.

Trainee takeaway

PSC cancer surveillance is annual when stable and immediate when the disease changes.

Frequently asked questions

How often should imaging be performed?

AASLD recommends annual imaging for adults with large-duct PSC.

Which modality is preferred?

MRI/MRCP.

Is CA 19-9 enough?

No; it is an adjunct and has important limitations.

References

1. Thomson ABR. Guideline-Based Management in Hepatology. CAPstone Academic Publishers; 2015.

2. Thomson ABR. Endoscopy and Diagnostic Imaging. Part II. CAPstone Academic Publishers; 2012.

3. Bowlus CL, et al. AASLD Practice Guidance on PSC and Cholangiocarcinoma. Hepatology. 2023.

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions